As of May 16, 2018 Angiodynamics Inc (NASDAQ:ANGO) Sellers Reduced Their Shorts By 1.32%

May 16, 2018 - By Norman Soto

AngioDynamics, Inc. (NASDAQ:ANGO) Corporate Logo

Big Money Sentiment increased to 1.26 in Q4 2017. It has change of 0.09, from 2017Q3’s 1.17. The ratio increased due to AngioDynamics, Inc. positioning: 14 sold and 48 reduced. 22 funds acquired stakes and 56 increased stakes. Investors holded 33.36 million in 2017Q3 but now own 33.90 million shares or 1.62% more.
State Board Of Administration Of Florida Retirement holds 0% of its capital in AngioDynamics, Inc. (NASDAQ:ANGO) for 35,168 shs. 28,897 are held by Manufacturers Life Ins The. Glenmede Tru Company Na invested in 502 shs. Geode Management Ltd Com invested in 0% or 435,379 shs. Meeder Asset Management has invested 0% of its capital in AngioDynamics, Inc. (NASDAQ:ANGO). Ny State Teachers Retirement System stated it has 0% of its capital in AngioDynamics, Inc. (NASDAQ:ANGO). Sterling Lc, North Carolina-based fund reported 37,524 shs. Tudor Investment Et Al has 30,168 shs. Regions Fincl has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Kennedy stated it has 0.04% in AngioDynamics, Inc. (NASDAQ:ANGO). Texas Yale reported 20,086 shs. Legal And General Grp Plc accumulated 0% or 66,850 shs. Fmr Limited Liability Company reported 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Brinker Capital has 18,137 shs. Fny Managed Accounts Limited Liability stated it has 0% of its capital in AngioDynamics, Inc. (NASDAQ:ANGO).

It was noted a decrease on Angiodynamics Inc (NASDAQ:ANGO)’s shorted shares with 1.32%. FINRA issued shorted shares of ANGO’s total 1.89M shares. Previously was reported down change of 1.32% from 1.92M shares. Angiodynamics Inc (NASDAQ:ANGO) has 164,600 shares average volume. It’ll cost 12 days for ANGO to restore its former position. Float short on Angiodynamics Inc is 5.21%.

ANGO touched $19.93 during the last trading session after $0.2 change.Currently AngioDynamics, Inc. is downtrending after 2.41% change in last May 16, 2017. ANGO has 56,197 shares volume. The stock underperformed the S&P 500 by 13.96%.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally.The company has $733.51 million market cap. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.The P/E ratio is 553.61. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

In total 3 analysts cover Angiodynamics (NASDAQ:ANGO). “Buy” rating has 1, “Sell” are 0, while 2 are “Hold”. (NASDAQ:ANGO) has 33% bullish analysts. 5 are the (NASDAQ:ANGO)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. On Monday, April 2 the firm has “Hold” rating given by Canaccord Genuity. On Friday, January 5 the firm has “Hold” rating by Craig Hallum given. On Thursday, March 29 the firm earned “Hold” rating by Canaccord Genuity. On Tuesday, April 3 Raymond James upgraded AngioDynamics, Inc. (NASDAQ:ANGO) to “Outperform” rating. On Thursday, January 4 the rating was maintained by Canaccord Genuity with “Hold”.

AngioDynamics, Inc. (NASDAQ:ANGO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.